Date: 2013-09-10
Type of information: Collaboration agreement
Compound: upcyte® cells - Sernova\'s Cell Pouch™
Company: Medicyte (Germany) Sernova (Canada)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: collaboration
Action mechanism:
Disease: hemophilia A
Details: * On September 10, 2013, Sernova and Medicyte have announced that the companies have entered into a Material Transfer Agreement (MTA) to jointly evaluate the use of Medicyte\'s upcyte® cells in Sernova\'s Cell Pouch™ for the treatment of patients with haemophilia A. The two companies have also entered into a nonbinding term sheet outlining the general terms of a collaboration for the pre-clinical and clinical development of the novel Cell Pouch™/upcyte® combination product for the treatment of haemophilia A. The parties intend to complete negotiations of a definitive agreement while initial research is being carried out under the terms of the MTA. Development of a product capable of producing an effective level of Factor VIII within the Cell Pouch™ environment has the potential to provide haemophilia A patients with better protection against dangerous episodes of excessive bleeding and greatly reduce annual therapy costs.
Continuation of the parties\' joint studies beyond the MTA is subject to negotiation and execution of a definitive collaboration agreement.
Financial terms:
Latest news:
